Overview
Achieve submitted NDA for cytisinicline to FDA, marking a major milestone
Co raised $49.3 mln in public offering to advance cytisinicline
Q2 loss per share misses estimates; net loss and loss from operations beat estimates, per LSEG data
Outlook
Achieve expects funding to support operations into H2 2026
Result Drivers
NDA SUBMISSION - Achieve submitted NDA for cytisinicline to FDA, marking a major milestone
PARTNERSHIP - Co partnered with Omnicom to streamline cytisinicline launch, aiming to reduce costs and optimize performance
PUBLIC OFFERING - Achieve raised $49.3 mln in public offering to support cytisinicline advancement
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | Miss | -$0.37 | -$0.36 (5 Analysts) |
Q2 Net Income | Beat | -$12.72 mln | -$12.90 mln (5 Analysts) |
Q2 Income From Operations | Beat | -$12.56 mln | -$13.10 mln (5 Analysts) |
Q2 Operating Expenses | $12.56 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Achieve Life Sciences Inc is $14.00, about 81.1% above its August 6 closing price of $2.64
Press Release: ID:nGNX7YwnfP
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)